PDS BIOTECHNOLOGY CORP (PDSB) Stock Analyst Earnings Estimates
NASDAQ:PDSB - Nasdaq - US70465T1079 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A 5,518.68% | N/A 122.42% | N/A 196.75% | N/A 14.41% | |||||||||||
| EBITDA YoY % growth | -13.16M | -26.45M -100.99% | -39.41M -49.00% | -51.79M -31.41% | -30.92M 40.30% | -14.91M 51.78% | -14.88M 0.20% | -21.43M -44.02% | -41.62M -94.21% | -42.988M -3.29% | N/A 6.28% | N/A -18.23% | N/A -17.99% | N/A -19.42% | N/A -12.92% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -13.19M | -26.5M -100.91% | -39.51M -49.09% | -51.97M -31.54% | -31.09M 40.18% | -15.01M 51.72% | -14.9M 0.73% | -21.44M -43.89% | -41.67M -94.36% | -43.045M -3.30% | N/A 7.86% | N/A -14.57% | N/A -19.48% | N/A -28.79% | N/A -11.89% | N/A 125.73% | N/A 611.54% | N/A 265.09% | N/A 16.19% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | -27.00 85.25% | -33.60 -24.44% | N/A | N/A | -0.99 31.65% | -0.63 36.36% | -1.45 -130.16% | -1.39 4.14% | N/A 18.00% | N/A -16.55% | N/A 3.78% | N/A -17.29% | N/A -2.72% | N/A 129.14% | N/A 604.55% | N/A 152.26% | N/A 15.98% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.30 14.76% | -0.34 -13.33% | -0.34 -49.31% | -0.35 -19.59% | -0.35 -18.52% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -10.71M -3.48% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -9.808M 5.76% | -10.696M -5.92% | -11.016M -26.85% | -11.385M -11.85% | -11.732M -19.62% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.29 17.14% | -0.28 | -0.01 | -2.15% |
| Q2 2024 Q2Q % growth | -0.23 37.84% | -0.34 | 0.11 | 33.29% |
| Q1 2024 Q2Q % growth | -0.30 6.25% | -0.37 | 0.07 | 19.79% |
| Q4 2023 Q2Q % growth | -0.35 47.76% | -0.45 | 0.10 | 21.76% |
| Q3 2023 Q2Q % growth | -0.35 -34.62% | -0.45 | 0.10 | 23.01% |
| Q2 2023 Q2Q % growth | -0.37 -85.00% | -0.35 | -0.02 | -4.50% |
| Q1 2023 Q2Q % growth | -0.32 | -0.31 | -0.01 | -2.62% |
| Q4 2022 Q2Q % growth | -0.67 -204.55% | -0.29 | -0.38 | -128.76% |
| Q3 2022 Q2Q % growth | -0.26 -8.33% | -0.29 | 0.03 | 9.43% |
| Q2 2022 Q2Q % growth | -0.20 -566.67% | -0.29 | 0.09 | 30.39% |
| Q1 2022 Q2Q % growth | -0.32 -128.57% | -0.23 | -0.09 | -40.06% |
| Q4 2021 Q2Q % growth | -0.22 -22.22% | -0.25 | 0.03 | 10.75% |
| Q3 2021 Q2Q % growth | -0.24 -4.35% | -0.21 | -0.03 | -14.78% |
| Q2 2021 Q2Q % growth | -0.03 84.21% | -0.18 | 0.15 | 83.12% |
| Q1 2021 Q2Q % growth | -0.14 64.10% | -0.19 | 0.05 | 26.80% |
| Q4 2020 Q2Q % growth | -0.18 78.57% | -0.19 | 0.01 | 5.46% |
| Q3 2020 Q2Q % growth | -0.23 79.09% | -0.14 | -0.09 | -61.06% |
| Q2 2020 Q2Q % growth | -0.19 | -0.23 | 0.04 | 19.01% |
| Q1 2020 Q2Q % growth | -0.39 | -0.15 | -0.24 | -154.90% |
| Q4 2019 Q2Q % growth | -0.84 | -0.94 | 0.10 | 10.97% |
| Q3 2019 Q2Q % growth | -1.10 | -0.84 | -0.26 | -31.52% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 3.15% | 5.65% | 0.75% | 5.56% |
| Revenue | N/A | N/A | N/A | N/A |